What is the appropriate management of Stenotrophomonas maltophilia isolated from urine?

Management of Stenotrophomonas maltophilia in Urine

For S. maltophilia isolated from urine, first distinguish colonization from true infection based on clinical symptoms, then treat only symptomatic infections with trimethoprim-sulfamethoxazole (TMP-SMX) as first-line therapy, or consider combination therapy for severe cases. 1, 2

Distinguishing Colonization from Infection

The critical first step is determining whether S. maltophilia represents colonization versus true urinary tract infection:

Indicators of True Infection (requiring treatment):

• Fever (present in 100% of documented S. maltophilia UTIs) 3
• Dysuria, urgency, frequency, or suprapubic pain 4
• Flank pain or costovertebral angle tenderness (suggesting pyelonephritis) 4
• Systemic signs: sepsis syndrome (47% of cases), neutrophilia in non-neutropenic patients (70%), or bacteremia (13%) 3
• Presence of neutropenia or structural urinary abnormalities (significantly associated with infection rather than colonization) 3

Indicators of Colonization (may not require treatment):

• Asymptomatic bacteriuria in catheterized patients 4
• Isolation in patients receiving broad-spectrum antibiotics inactive against S. maltophilia 3
• Absence of fever, pyuria, or systemic symptoms 3

Risk Stratification

High-risk patients more likely to have true infection include: 3

• Neutropenic patients
• Those with urinary structural abnormalities (obstruction, foreign bodies, incomplete voiding)
• Genitourinary malignancy patients
• Recent urinary catheterization
• Recent urological instrumentation 4

Treatment Approach

For Symptomatic Uncomplicated S. maltophilia UTI:

First-line monotherapy:

• TMP-SMX 160/800 mg twice daily for 7-14 days (14 days for males when prostatitis cannot be excluded) 4, 5, 6
• Susceptibility rates remain favorable: 91.3% susceptible in recent studies 7

Alternative monotherapy options if TMP-SMX contraindicated:

• Levofloxacin (80-100% susceptibility, though 20% may show intermediate susceptibility) 7, 6
• Minocycline - demonstrated non-inferiority to TMP-SMX in comparative studies with 30% treatment failure rate versus 41% for TMP-SMX (P=0.67) 8

For Severe/Complicated S. maltophilia UTI:

The 2024 IDSA guidance recommends combination therapy for severe infections: 1, 2

Preferred combination approaches:

• TMP-SMX plus levofloxacin 1, 2
• TMP-SMX plus minocycline 1, 2
• Ceftazidime-avibactam plus aztreonam (CZA-ATM) as monotherapy alternative 2
• Cefiderocol as part of combination therapy 2

Rationale for combination therapy: Recent pharmacokinetic/pharmacodynamic studies question current clinical breakpoints for TMP-SMX, levofloxacin, and minocycline, leading IDSA to recommend these agents only as combination therapy for severe infections 2

Treatment Duration:

• Uncomplicated UTI: 7 days 4
• Complicated UTI or males: 7-14 days (14 days when prostatitis cannot be excluded) 4
• Shorter duration (7 days) acceptable when patient is hemodynamically stable and afebrile for ≥48 hours 4

Management of Underlying Factors

Mandatory interventions: 4

• Remove or exchange urinary catheter if present
• Address urological abnormalities (obstruction, foreign bodies)
• Correct structural abnormalities when feasible
• Discontinue unnecessary broad-spectrum antibiotics

Clinical Course Expectations

S. maltophilia UTI typically presents with severe clinical manifestations: 3

• Fever in 100% of cases
• Sepsis syndrome in 47%
• Bacteremia in 13%
• Mortality rate of 7% in infected patients (though can reach 35% in high-risk populations) 3, 7

However, response to appropriate treatment is typically prompt 3

Critical Pitfalls to Avoid

• Do not treat asymptomatic bacteriuria unless patient is pregnant or undergoing invasive urologic procedures with expected mucosal bleeding 9
• Do not use fluoroquinolones empirically if patient has used them in the last 6 months or is from a urology department 4
• Do not rely on monotherapy for severe infections - the 2024 IDSA guidance shifted away from monotherapy based on PK/PD concerns 1, 2
• Do not use tigecycline - recent guidance evolution reflects shift away from agents with unfavorable pharmacokinetic profiles 10
• Avoid ticarcillin-clavulanic acid as it is no longer widely available, though historically considered an option 5, 6

Monitoring and Follow-up

• Obtain urine culture and susceptibility testing before initiating therapy 4
• Reassess if symptoms do not resolve within 48 hours of appropriate therapy 4
• Consider infectious diseases consultation, as S. maltophilia management remains challenging without standardized treatment protocols 11, 1